Infection with Borrelia burgdorferi, the bacterium responsible for Lyme disease, can cause lasting alterations in bone marrow cells even after antibiotic treatment, according to a mouse-model study led by researchers at Tufts University School of Medicine and published in the journal iScience. Bone marrow serves as the primary tissue where many of the body’s immune cells are produced, and these persistent post-infection alterations potentially modify how the immune system responds to future threats. The peer-reviewed findings provide new clues into how a bacterial infection can exert continuing biological effects after the microbes are cleared, offering insights that could eventually help scientists identify biological markers associated with prolonged illness and pinpoint potential treatment targets.
To investigate the long-term effects of Lyme disease, the research team utilized a mouse model to analyze bone marrow cells following bacterial infection, evaluating both untreated mice and animals that subsequently received antibiotics. The investigators discovered that exposure to Borrelia burgdorferi produced distinct epigenetic changes—chemical modifications that directly influence which specific genes are turned on or off—in bone marrow cells. Senior author Tanja Petnicki-Ocwieja, a research assistant professor of molecular biology and microbiology at Tufts University School of Medicine, explained that a lifetime of infections and inflammatory exposures creates editing marks in the immune system’s historical record of prior encounters. Petnicki-Ocwieja noted that these epigenetic changes imprinted within the bone marrow may essentially revise the immune system’s biography and govern how it responds over time.
These cellular modifications were especially pronounced in macrophages, specialized immune cells generated in the bone marrow that act as early responders during an infection. Under standard conditions, macrophages detect foreign threats, engulf invading microbes, and release chemical signals designed to summon other immune cells to destroy invaders. However, macrophages produced by mice previously exposed to Borrelia burgdorferi exhibited suppressed expression of genes involved in driving this inflammatory defense. This suppression of inflammatory gene expression persisted for at least 15 weeks following the initial infection. As Petnicki-Ocwieja described, while macrophages sound alarm bells to summon other immune cells upon first encountering the bacteria, subsequent epigenetic imprinting in the bone marrow causes them to sound fewer alarms.
Significantly, this altered immune response was also detected in experimental mice that received antibiotic treatment following infection. The observation that treated animals still displayed altered macrophage responses indicates that these epigenetic shifts occur relatively early during the course of infection and do not require prolonged or ongoing active bacterial illness. First author Yuelin Zhong, a PhD student in immunology at the Tufts Graduate School of Biomedical Sciences, emphasized that an individual’s initial exposure to Borrelia burgdorferi appears sufficient to cause long-term consequences for the immune response.
Despite the findings observed in the animal model, the authors underscored that the study does not establish that identical immune alterations occur in human patients with Lyme disease or that such mechanisms cause persistent symptoms. To determine whether these epigenetic modifications are relevant to human illness, the investigators plan to examine epigenetic markers in human clinical cohorts following Lyme disease infection. Petnicki-Ocwieja will collaborate with study co-author Linden Hu, the Paul and Elaine Chervinsky Professor of Immunology at the School of Medicine, to analyze circulating immune cells obtained from blood samples in a large, Tufts-led multi-institution clinical study that monitors patients for up to 15 months after receiving a Lyme disease diagnosis.
Through this human patient research, the investigators hope to determine whether individuals who develop prolonged symptoms exhibit different epigenetic signatures compared to individuals who recover without lasting symptoms. Petnicki-Ocwieja stated that the ultimate goal is to sequence these epigenetic marks to establish comprehensive profiles of how Lyme disease influences an individual’s immune system, allowing comparisons between patients experiencing long-term symptoms and those who have fully recovered. If distinct epigenetic profiles are identified, they could yield vital explanations for why certain patients experience lingering post-treatment manifestations—such as persistent fatigue, joint pain, or cognitive difficulties—while helping researchers establish objective biomarkers for prolonged illness and develop new therapeutic approaches.
The study received financial support from the Global Lyme Alliance, a Tufts Graduate School of Biomedical Sciences Dean’s Fellow Award, and several awards from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases. Regarding study disclosures, co-author Linden Hu receives support for contract research services through Tufts University from companies including Moderna, Sanofi, Tarsus, and Massbiologics for unrelated vaccine and drug development projects, while the authors noted that the content remains solely their responsibility and does not necessarily represent the official views of their funding organizations.
Subject of Research: Epigenetic reprogramming of bone marrow cells caused by Borrelia burgdorferi infection
Article Title: Lyme disease rewrites the body’s immune response
Article References: Lyme disease rewrites the body’s immune response. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: Borrelia burgdorferi, Lyme disease, bone marrow, epigenetic changes, macrophages, immune response, antibiotic treatment, gene expression, inflammatory response, Tufts University School of Medicine, Tanja Petnicki-Ocwieja, Yuelin Zhong, Linden Hu, iScience, mouse model, biomarkers, persistent symptoms, immune cells
News Source: Juliet Wilcox. (November 20, 2026). Lyme Disease Bacterium Triggers Lasting Epigenetic Changes in Mouse Bone Marrow. Scienmag.



